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Introduction
Derived from the French Lilac plant Galega 
Ofﬁcinalis, metformin (N,N-dimethylimidodi-
carbonimidic diamide) has widely established 
itself as a safe as well as clinically effec-
tive oral glucose lowering agents. Used for 
55 years in the United Kingdom (although 
for only the last eighteen years or so in 
the United States),1-3 this drug has been 
virtually uniformly advocated as a ﬁrst line 
agent in the management of type 2 diabetes 
(T2DM) by local, national and international 
treatment guidelines. This review will seek 
to address the evidence underpinning its 
widespread use in T2DM patients, as well 
as potentially exciting new roles in type 1 
diabetes (T1DM) and beyond.
Pharmacology
Perhaps surprisingly, the mechanism of 
action of metformin had remained obscure 
until relatively recently. This biguanide is 
now recognised as a weak activator of an 
important, ubiquitous, phylogenetically con-
served serine/threonine protein kinase called 
AMP-activated protein kinase (AMPK).4 Act-
ing as a gauge of systemic and cellular en-
ergy status, AMPK is activated by an increase 
in intracellular adenosine monophosphate / 
adenosine-5’-triphosphate (AMP/ATP) ratio, 
and serves to protect cellular functions under 
energy restricted conditions by switching 
from an anabolic to a catabolic state. The 
latter is achieved through phosphorylation 
of key metabolic enzymes and transcription 
factors/co-activators modulating gene ex-
pression.5 Following hepatic uptake through 
the organic cationic transporter 1 (OCT1),6 
metformin exerts additional speciﬁc and 
AMPK independent inhibition of complex 1 
of the respiratory chain,7 leading to an acute 
and transient inhibition of gluconeogenesis, 
as well as an inhibition of key gluconeogenic 
enzymes.8, 9 AMPK activation also reduces 
hepatic lipogenesis through phosphorylation 
and inactivation of acetyl-Co-A carboxylase 
4 while suppressing lipogenic genes such as 
fatty acid synthase.10 
Cost effectiveness
Data from the Diabetes Prevention Pro-
gramme (DPP) suggests that metformin is 
cost-effective in individuals below the age 
of 65. Intervening with this drug over a 
lifetime is expected to prevent diabetes in 
8%, delay onset of T2DM by 3.4 years, in-
crease life expectancy by 0.2 year and reduce 
the cumulative incidence of coronary artery 
disease, stroke, amputation, end-stage renal 
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Abstract
Acting as a weak activator of AMP-activated protein kinase, 
metformin has established itself as a cost-effective ﬁrst line agent 
in the management of type 2 diabetes (T2DM). Besides slowing 
progression to this condition, its use is associated with improved 
survival and lower rates of myocardial infarction in T2DM, as well 
as beneﬁts in stable patients with heart failure. Metformin may 
play a valuable role in early nephropathy, non-alcoholic fatty liver 
disease and as adjunct therapy in type 1 diabetes. It is increasingly 
advocated in patients with gestational diabetes and polycystic ovary 
syndrome. Its role as an anti-cancer agent remains controversial.
Educational aims
Abbreviations
s  To highlight the mechanism of action of metformin
s  To identify metformin’s role as an oral glucose lowering agent with favourable 
pleiotropic effects on cardiovascular outcomes.
s  To discuss potential new roles for this drug in type 1 diabetes, as well as in the ﬁelds 
of obstetrics and gynaecology, nephrology, hepatology and oncology
s  To discuss the cost-effectiveness and safety of metformin pharmacotherapy, with 
particular reference to established prescription guidelines
AMP adenosine monophosphate
AMPK AMP-activated protein kinase
ATP adenosine-5’-triphosphate 
BMI body mass index
DARTS Diabetes and Audit in Research Tayside Scotland
DPP Diabetes Prevention Programme
eGFR estimated glomerular ﬁltration rate
HbA1c glycosylated haemoglobin
HF heart failure
HOME Hyperinsulinaemia: the Outcome of its Metabolic 
Effects
IGT impaired glucose tolerance
MIG Metformin in Gestational Diabetes
mTOR mammalian Target Of Rapamycin
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatosis
OCT1 organic cationic transporter 1
OR Odds ratio
PRESTO Prevention of Restenosis with Tranilast and 
its Outcomes
QALY quality-adjusted life year
RR relative risk
T1DM type 1 diabetes mellitus
T2DM  type 2 diabetes mellitus
UKPDS United Kingdom Prospective Diabetes Study
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disease and blindness by 2%, 3%, 16%, 17% 
and 16% respectively.11 The estimated cost 
per quality-adjusted life year (QALY) gained 
for (generic) use of metformin over a lifetime 
is $1755 compared to placebo.11 
Metformin in pre-diabetes and obesity
The DPP reported that metformin prescribed 
at a dose of 850mg twice daily decreased 
progression from impaired glucose tolerance 
(IGT) to diabetes by 31% over three years. 
Beneﬁts were greater in patients with a body 
mass index (BMI) exceeding 35 kg/m2 (mean 
reduction of 53%) compared with those 
whose BMI ranged between 22 and 30 kg/
m2 (mean reduction 3%). Metformin therapy 
was as effective as lifestyle intervention in 
younger individuals and those with a higher 
BMI.12 These effects appear to be durable, as 
demonstrated in the ten-year follow-up data 
of the DPP, resulting in comparable diabetes 
incidence rates between metformin-treated 
individuals and those adopting intensive 
lifestyle interventions.13
Metformin in type 2 diabetes
The United Kingdom Prospective Diabetes 
Study (UKPDS) was the ﬁrst major study to 
suggest a cardiovascular beneﬁt in T2DM. 
Randomising 1704 overweight T2DM patients 
to initial treatment with metformin (342 
patients), sulphonylurea or insulin (951 
patients), or dietary measures alone (411 
patients), metformin therapy (but not sul-
phonylurea/insulin therapy) was associated 
with a 32% lower incidence of any diabetes 
related endpoint (micro- and macrovascular) 
(p = 0.002), 42% fewer diabetes related 
deaths (p = 0.017), 36% lower all cause mor-
tality (p = 0.011), and 39% fewer myocardial 
infarctions (MIs) (p = 0.010).14 These effects 
persisted after 10 years of follow-up (risk 
reductions of 21% for any diabetes related 
end-point (p = 0.01), 33% for myocardial 
infarction (p = 0.005), and 27% for death 
from any cause (p = 0.002), despite the fact 
that differences in glycaemic control (as as-
sessed by glycosylated haemoglobin [HbA1c] 
levels) were no longer evident after one year 
of follow-up.15 These potential cardiovascu-
lar beneﬁts in high risk patients with T2DM 
have been corroborated by subgroup analyses 
of other trials, such as the Prevention of 
Restenosis with Tranilast and its Outcomes 
(PRESTO) trial. In a retrospective review of a 
subgroup of 1997 participants with diabetes 
who had undergone a percutaneous coronary 
intervention, those treated with metformin 
(with or without additional therapy, n = 887) 
were at a signiﬁcantly lower risk of death 
(OR 0.39 [95% CI 0.19, 0.77]; p = 0.007) 
and myocardial infarction (OR 0.31 [95% CI 
0.15, 0.66]; p = 0.002) compared with those 
treated with insulin and /or sulphonylurea (n 
= 1110).16 Data from the Diabetes and Audit 
in Research Tayside Scotland (DARTS) study 
reported that mortality was signiﬁcantly 
lower after ﬁve years among drug-naive 
T2DM patients initially treated with metfor-
min compared with a sulphonylurea.17 McAfee 
et al reached similar conclusions, reporting a 
23% reduction in the composite endpoint of 
myocardial infarction and coronary artery re-
vascularisation in metformin treated patients 
compared with sulphonylurea therapy after 
ﬁve years of follow-up.18 Use of metformin in 
higher risk T2DM patients with heart failure 
was associated with a signiﬁcant reduction 
in all-cause hospitalization at one  year (OR 
0.85 [95% CI  0.76, 0.95]; p = 0.004) com-
pared with non-sensitisers (sulphonylureas, 
non-sulphonylurea insulin secretagogues, 
alpha glucosidase inhibitors or insulin) in a 
systematic review and meta-analysis of eight 
controlled studies.19 In a similar vein, Eurich 
et al reported that metformin monotherapy 
in this setting translates into a lower risk 
of mortality (HR 0.70 [95% CI 0.54, 0.91]) 
as well as a lower risk of the composite 
outcome of deaths or hospitalization (HR 
0.83 [95% CI 0.70, 0.99]) compared to 
sulphonylurea therapy.20 In a retrospective 
study of 8063 insulin-treated patients with 
no prior history of heart failure (HF), Nichols 
et al, reported that metformin therapy 
reduced the congestive HF rate ratio to 0.63 
(95% CI 0.37, 1.07), a development which 
is particularly desirable given that initial 
insulin therapy was associated with a higher 
incidence of HF.21
Is there a role for adjunct metformin in 
type 1 diabetes?
An ever increasing proportion of T1DM 
patients harbour a phenotypic and metabolic 
proﬁle typical of patients with the metabolic 
syndrome. Indeed insulin resistance has 
been shown to accelerate progression to 
macrovascular and microvascular outcomes 
in T1DM.22 These observations generated 
considerable interest in a potential role for 
adjunct metformin, also given that achiev-
ing tight glycaemic control is particularly 
challenging in this setting, particularly with 
its attendant risk of hypoglycaemia. Data 
from the Hyperinsulinaemia: the Outcome of 
its Metabolic Effects (HOME) study was reas-
suring, albeit comparing outcomes in 390 
insulin treated T2DM patients randomised 
to treatment with metformin or placebo 
therapy and followed up for 4.3 years. Use of 
this biguanide led to signiﬁcant reductions 
in body weight (-3.07 kg [range -3.85 to 
-2.28]; p<0.001), HbA1c (mean -0.4% [95% 
CI = -0.25, -0.55]; p < 0.001) and insulin 
requirements (mean -19.63 IU/day [95% CI 
= -14.36, -24.91]; p < 0.001). Additionally, 
metformin was reported to decrease macro-
vascular morbidity and mortality (HR 0.61 
[95% CI = 0.40, 0.94]; p = 0.02), an effect 
that was partly explained by the difference 
in weight.23 While prospective data remains 
scanty, a formal meta-analysis of available 
studies published by the undersigned sug-
gested that use of adjunct metformin use in 
T1DM is associated with a signiﬁcant reduc-
tion in total daily insulin dose (6.6 units / 
day; p < 0.001), albeit no improvement in 
glycaemic control.24 
Polycystic ovary syndrome and gestational 
diabetes
Affecting at least 5-15% of women of child-
bearing age, insulin resistance is a hallmark 
(though not imperative feature) of this 
condition characterised by hyperandrogen-
ism, hirsutism, acne, menstrual irregularities 
and infertility. A meta-analysis of 31 clinical 
trials demonstrated that metformin therapy 
may increase ovulation, improve menstrual 
cyclicity and reduce serum androgen levels 
in these patients.25 A recently published sys-
tematic review of metformin use in pregnant 
women with the polycystic ovary syndrome 
reported lower pooled risks of early preg-
nancy loss (OR 0.32; [95% CI 0.19, 0.55]), 
gestational diabetes (OR 0.37; [95% CI 0.25, 
0.56]),  pre-eclampsia (OR 0.53; [95% CI 
0.30, 0.95]) and preterm delivery (OR 0.30 
[95% CI 0.13, 0.68]).26 Current guidelines 
tend to advocate a role for metformin in 
the management of gestational diabetes.2, 27 
Despite concerns that metformin crosses the 
placenta, two meta-analyses (one in women 
prescribed metformin monotherapy, and the 
other recruiting women using metformin 
and/or a sulphonylurea) have not reported 
an increase in congenital malformations 
or neonatal deaths 28, 29. The Metformin in 
Gestational Diabetes (MIG) trial reported 
no signiﬁcant difference in the composite 
neonatal outcome of neonatal hypoglycae-
mia, respiratory distress,  need for photo-
therapy, birth trauma, 5-minute Apgar score 
< 7, or prematurity), albeit higher rates of 
preterm births and less weight gain among 
the 363 patients treated with metformin (± 
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supplemental insulin) compared to patients 
randomised to insulin therapy (n = 370).30 A 
recently published, albeit smaller (n = 94), 
trial largely showed that metformin improved 
glycaemic control (lower mean glucose levels 
throughout the day), with the added advan-
tages of less weight gain and lower rates 
of neonatal hypoglycaemia compared with 
insulin therapy.31
Metformin and cancer
Data from several studies suggests that met-
formin use is associated with signiﬁcantly 
lower incidence rates across multiple can-
cers. Two meta-analyses, integrating results 
from several observational and randomised 
controlled trials, reported relative risks of 
0.69 (95% CI 0.61, 0.79) 32 and 0.67 (95% 
CI 0.53, 0.85) 33 respectively. While impres-
sive, such results should be interpreted with 
caution, given the inherent limitations of 
observational studies, and the potential 
of including studies with ‘immortal time 
bias’. At least one study employing statisti-
cal techniques which avoided immortal 
time bias reported no association between 
metformin use and cancer incidence.34 At a 
cellular level, the anti-neoplastic action of 
metformin appear to be mediated by both 
AMPK-dependent and -independent mecha-
nisms, leading to an inhibition of the cell 
cycle (through a reduction in cyclin D1 level) 
and mammalian Target Of Rapamycin (mTOR) 
signalling, a stimulation of the p53/p21 axis, 
and a suppression of fatty acid synthesis, an-
giogenesis,  inﬂammation, hyperinsulinaemia 
and prevalent insulin growth factors.35
Metformin and non-alcoholic fatty liver 
disease
The majority of patients with T2DM are 
characterised by non-alcoholic fatty liver 
disease (NAFLD) and up to 50% may develop 
non-alcoholic steatohepatosis (NASH), a har-
bringer of cirrhosis. Metformin prescription 
in patients with NAFLD may translate into a 
reduction in plasma aminotransferases, albeit 
without evidence of improvement in liver 
histology. 36-38
Metformin and nephropathy
Metformin should be prescribed with caution 
in individuals with an estimated glomerular 
ﬁltration rate (eGFR) ranging between 30 
and 45 mls/min/1.73m2 and is absolutely 
contraindicated if eGFR <30 mls/min/1.73m2. 
Nonetheless, data from animal models 
suggests that metformin pharmacotherapy 
ameliorates tubular injury associated with 
hyperglycaemia (partly by reducing oxygen 
consumption and hypoxia-inducible fac-
tor- 1 expression) 39 as well as reactive 
oxygen species-mediated lipotoxicity of renal 
podocytes.40 Both mechanisms underpin 
the development of diabetic nephropathy. 
Additionally, data from murine models sug-
gests that metformin reduces cystic growth 
in autosomal dominant polycystic kidney 
disease.41 Such promising roles remain to be 
conﬁrmed in clinical studies.
Adverse effects
A Cochrane review has largely dispelled the 
myth that the beneﬁts of metformin may be 
offset by an unacceptably high risk of lactic 
acidosis. Indeed, the authors reported no 
additional risk of developing this complica-
tion in  prospective comparative trials or 
from observational cohort studies, provided 
metformin is prescribed in the appropriate 
setting.42 To this effect, use of this oral glu-
cose lowering agent is not recommended in 
acute situations associated with hypoxia or a 
tendency for acidosis (such as sepsis, acute 
heart failure, cardiogenic shock, respiratory 
failure) as well as in moderate to severe 
renal impairment (as outlined earlier). 
Gastro-intestinal adverse effects (bloating, 
diarrhoea, abdominal cramps, ﬂatulence) are 
best avoided if metformin is dosed gradually 
over a few days to weeks. Tolerability may 
be improved by switching to an extended 
release formulation.43 Vitamin B12 deﬁ-
ciency is a recognised, albeit rare, adverse 
effect, and should be borne in mind in pa-
tients with macrocytic anaemia, peripheral 
neuropathy and cognitive impairment.44,45
Conclusion - the way forward
Metformin’s pivotal role in the management 
of T2DM is clearly established, and likely 
to remain undisputed, at least in the near 
future. Available evidence suggests that it 
is safer than initially thought, particularly 
if prescribed in the right clinical setting. 
A better understanding of the mechanisms 
underpinning its diverse actions at a cel-
lular level, particularly in humans, is likely 
to unravel exciting new roles for this cheap, 
widely prescribed, biguanide. 
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